{
  "document": "Foundation_45",
  "Genomic Findings": [
    { "Name": "CTNNB1 S45del", "Clinical": [], "No Clinical": [] },
    {
      "Name": "ASXL1 G645fs*58, R549fs*2",
      "Clinical": [],
      "No Clinical": []
    },
    { "Name": "CUL3 L210fs*20", "Clinical": [], "No Clinical": [] },
    { "Name": "FLCN R477*", "Clinical": [], "No Clinical": [] },
    { "Name": "FUBP1 S11fs*43", "Clinical": [], "No Clinical": [] },
    { "Name": "PTPRO Q484fs*14", "Clinical": [], "No Clinical": [] },
    { "Name": "SMARCA4 R1243W", "Clinical": [], "No Clinical": [] }
  ],
  "Biomakers findings": [
    {
      "Name": "Microsatellite statuse status - MSI-High",
      "Clinical": [
        "Atezolizumab",
        "Cemiplimab",
        "Durvalumab",
        "Nivolumab",
        "Pembrolizumab",
        "Dostarlimab"
      ],
      "No Clinical": ["Avelumab"]
    },
    {
      "Name": "Tumor Mutational Bur umor Mutational Burden - 34 Muts/Mb",
      "Clinical": [
        "Atezolizumab",
        "Cemiplimab",
        "Durvalumab",
        "Nivolumab",
        "Nivolumab + Ipilimumab",
        "Pembrolizumab",
        "Dostarlimab"
      ],
      "No Clinical": ["Avelumab"]
    }
  ],
  "k":4
}